Corrigendum to: Glutathione Increase and Seizure Burden Decrease in Patients with Intractable Epilepsy on Ketogenic Diet

Article information

J Epilepsy Res. 2023;13(2):63-64

Publication date (electronic) : 2023 December 31

doi : https://doi.org/10.14581/jer.23001.e1

Saman Hazany, MD ¹, Brittany DeClouette, MD ¹, Jessica Lowe, MPH ², Darryl H Hwang, PhD ¹, Paul E Kim, MD ¹, Stefan Bluml, PhD ³, Arthur Partikian, MD ²

¹Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

²Department of Pediatrics & Neurology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

³Department of Radiology, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

J Epilepsy Res 2023;13(1):1-6

https://doi.org/10.14581/jer.23001

In published article by Hazany S et al., there is an error in the data value and location of the ‘Absolute level’ column in Table 1. Modify the data values and locations as follows.

Before correction:

After correction:

Additionally, the CI abbreviation in Figure 2 of the above article is modified from ‘confidence interval’ to ‘complex I’.

The authors would like to apologize for any inconvenience caused.

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Patient	Clinical data					MRS data

	Age (years)	Seizures (months)	Average seizure duration (minutes)	Diet duration (months)	Serum βHB (mM/L)	GSH (parietal white matter)		NAA/tCr	βHB absolute level (IU)

						Absolute level (IU)	GSH/tCr
1
Pre-KD	42	3–5	1–5	4	0.15		0.02	GM: 1.46	GM: 0.49
						GM: 0.12 (SD: 268)
						WM: 0.65 (SD: 56)	0.07	WM: 1.30	WM: 0.00
Post-KD		1–2	0.5		0.12		0.33	GM: 1.57	GM: 0.07
						GM: 1.40 (SD: 35)
						WM: 1.50 (SD: 31)	0.19	WM: 1.28	WM: 0.02
2
Pre-KD	35	2–4	2–5	7	0.10		0.02	GM: 1.39	GM: 0.68
						GM: 0.10 (SD: 370)
						WM: 0.80 (SD: 39)	0.12	WM: 1.42	WM: 0.25
Post-KD		1–2	0.5		0.10–0.18		0.15	GM: 1.46	GM: 0.25
						GM: 0.70 (SD: 51)
						WM: 2.00 (SD: 16)	0.35	WM: 1.40	WM: 0.56

Patient	Clinical data					MRS data

	Age (years)	Seizures (months)	Average seizure duration (minutes)	Diet duration (months)	Serum βHB (mM/L)	GSH (parietal white matter)		NAA/tCr	βHB absolute level (IU)

						Absolute level (IU)	GSH/tCr
1
Pre-KD	42	3–5	1–5	4	0.15	GM: 0.12 (SD: 268)	0.02	GM: 1.46	GM: 0.49
						WM: 0.65 (SD: 56)	0.07	WM: 1.30	WM: 0.00
Post-KD		1–2	0.5		0.12	GM: 1.40 (SD: 35)	0.33	GM: 1.57	GM: 0.07
						WM: 1.50 (SD: 31)	0.19	WM: 1.28	WM: 0.02
2
Pre-KD	35	2–4	2–5	7	0.10	GM: 0.10 (SD: 370)	0.02	GM: 1.39	GM: 0.68
						WM: 0.80 (SD: 39)	0.12	WM: 1.42	WM: 0.25
Post-KD		1–2	0.5		0.10–0.18	GM: 0.70 (SD: 51)	0.15	GM: 1.46	GM: 0.25
						WM: 2.00 (SD: 16)	0.35	WM: 1.40	WM: 0.56